All signs indicate that Ferring Pharmaceuticals is on the cusp of being market authorized for its biologic candidate against C. difficile infection.
Sanofi and Regeneron will be able to call themselves market leaders within atopic eczema treatment for children aged 6 months to 5 for years to come, according to Globaldata.
Three of Denmark’s biggest funds have come together for a yet unknown project, which includes the establishment of three new firms.
The company’s new chief executive has ambitions of reaching a DKK 2.5bn (USD 325m) revenue within the time frame.
The co-founder of Enochian Biosciences has been arrested and charged with murder for hire. Now, chairman of the board René Sindlev has spoken out about the arrest for the first time.
Demand for the diabetes medicine is already big, and the US-based company is also expected to apply for market authorization in the obesity indication. (Updated)
Results from a phase III trial in which Doseguide, an app solution developed by the Danish drugmaker, featured prominently are expected within a few weeks.
The Danish drugmaker’s best-selling medication Ozempic may be impacted by new national health insurance legislation.
A serious adverse event has been investigated, and Pfizer and partner Sangamo are ready to reopen a phase III trial with hemophilia A patients.
Should Russia cut off Europe from gas, Coloplast’s suppliers might suddenly face a problem – but CFO Anders Lonning-Skovgard can’t say to what extent. ALK’s main supplier would get off scot-free, says CEO Carsten Hellmann.
Sclerosis treatment Kesimpta, which was developed by Genmab, could surpass USD 2bn in revenue in the future, says the company selling the drug, Novartis.
The jury is still out on the relationship between the coronavirus and diabetes, though two new studies have certainly found an interesting link between them.
The US health authority has put a partial clinical hold on the company’s peanut allergy phase III trial until certain study changes have been made.
An analyst and a professor in vaccine design think the Danish drugmaker might have arrived late to the Covid-19 vaccine party, as CEO Paul Chaplin also lowers his ambitions.
One of the scientist who discovered the drug class that has risen in popularity within migraine treatment in recent time predicts a bright future for CGRP drugs.
Spanish dermatology group Almirall has administered the first dose in a phase I trial of a new potential treatment for autoimmune skin diseases.
Results from the first six months of a phase II trial of the potential booster were slated for end-August, but analysis has taken longer than expected.
Another round of positive study data for insulin icodec has cemented the company’s belief that a global approval process can be initiated at the start of next year, Novo Nordisk executive Martin Holst Lange tells MedWatch.
The company is currently waiting on phase III data for glepaglutide, which could open many doors for the company in the future.
A new head-to-head study demonstrates that iron deficiency drug Monofer is better than Ferinject, a competing treatment developed by Vifor Pharma. An ongoing EU antitrust investigation makes the results even more important, says Pharmacosmos.
Digging its heels in over the summer, the EMA’s expert committee is still of the opinion that almost 100 generic medicines need to be removed from market – though eight have been granted clemency.
The Danish vaccine maker is in dialogs with potential partners that could step in for the filling of vials or the production of bulk vaccines, should it become necessary.
According to plans, GSK veteran Luc Debruyne will begin as an observer to the board of the Danish drugmaker before being nominated as chairman in 2023.
Though monkeypox cases are on the decline, nations the world over have looked to Bavarian Nordic to build vaccine stockpiles for the future – which makes for a good financial foundation for the firm, says a Sydbank analyst.
On Monday, the biotech company said there would be no new financial report on Tuesday, the day one was scheduled to be released.
Manager for Process Support - 1st line support 
Pharmacovigliance (Associate) Director or Senior Specialist 
Pharmacovigilance & Regulatory Officer 
Product specialist 
Senior Manager, QA GMP 
Head of Commercial / Sales Manager, Denmark Calibration Technician Senior CMC & Device Project Manager 
Lab Manager Product specialist in Cardio Rhythm Management, Zealand 
Experienced IT Business Solutions Manager for the Danish Medicines Agency 
Chief Business Officer Ambitious Business Relationship Manager for the Danish Medicines Agency LIMS Super User for Operations at ALK 
Nordic Key Account Manager, Hollister & Dansac Senior Manager, System Change & Release Management 
Manager of QA, BHS Logistics Regulatory Project Manager eTMF Manager Drug Safety Associate 
Vice President, Medical Affairs Senior Drug Product Specialist 
KLIFO is looking for a Compliance Coordinator for our Glostrup office Pharmacovigilance & Regulatory Assistant with an interest in non-fiction 
Clinical Project Lead 
